ALEXANDRA MAKSIMOWSKI: Open Payments
NPI 1578023214 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,891 in 77 payments from 17 companies in 2025. Trend: 2023 $49 · 2024 $0 · 2025 $1,891
Food & beverage: $1,891
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $335 |
| GENZYME CORPORATION | 7 | $296 |
| GlaxoSmithKline, LLC. | 16 | $288 |
| Insmed, Inc. | 10 | $267 |
| Regeneron Healthcare Solutions, Inc. | 4 | $119 |
| Philips North America LLC | 6 | $118 |
| JAZZ PHARMACEUTICALS INC. | 3 | $79 |
| Grifols USA, LLC | 2 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Biogen, Inc. | 2 | $56 |
Products named: DUPIXENT, Arikayce, TRELEGY ELLIPTA, BREZTRI, AIRSUPRA, Vest Therapy Und, LEQEMBI, NUCALA.
Industry payments across AL — which companies pay providers there.
